SELECTION OF N-(PHOSPHONACETYL)-L-ASPARTATE RESISTANT CHINESE-HAMSTER MUTANTS IN THE PRESENCE OF THE URIDINE UPTAKE INHIBITOR DIPYRIDAMOLE

被引:0
|
作者
TESSERA, L [1 ]
MUCCIOLO, E [1 ]
BERTONI, L [1 ]
GIULOTTO, E [1 ]
机构
[1] UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV,I-27100 PAVIA,ITALY
关键词
PALA; DIPYRIDAMOLE; GENE AMPLIFICATION; DRUG RESISTANCE; CHINESE HAMSTER;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In mammalian cells selected in culture for resistance to PALA the CAD gene is amplified and these cells are a widely used model system to study gene amplification. Selection of resistant mutants is routinely performed in medium supplemented with dialyzed serum, because the cytotoxic effect of PALA is reversed by uridine, which is contained in serum. We have shown that in Chinese hamster cells dipyridamole reduced uridine uptake to less than 5% with limited effect on cell survival. Moreover, in medium supplemented with complete serum and 10 mu M dipyridamole the toxicity of PALA was similar to that obtained in medium containing dialyzed serum. We then used 10 mu M dipyridamole to inhibit uridine uptake during selection of PALA resistant colonies and found that both the frequency and the type of mutants were as those obtained in the presence of dialyzed serum. In particular, in the five mutants tested, the mechanism of resistance of PALA was amplification of the CAD gene.
引用
收藏
页码:189 / 192
页数:4
相关论文
共 50 条
  • [1] SERUM URIDINE LEVELS IN PATIENTS RECEIVING N-(PHOSPHONACETYL)-L-ASPARTATE
    KARLE, JM
    ANDERSON, LW
    ERLICHMAN, C
    CYSYK, RL
    CANCER RESEARCH, 1980, 40 (08) : 2938 - 2940
  • [2] STRUCTURE OF THE INHIBITOR OF ASPARTATE-TRANSCARBAMYLASE N-(PHOSPHONACETYL)-L-ASPARTATE
    ZANOTTI, G
    MONACO, HL
    FOOTE, J
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (25) : 7900 - 7904
  • [3] PROPERTIES OF SINGLE-STEP MUTANTS OF SYRIAN-HAMSTER CELL-LINES RESISTANT TO N-(PHOSPHONACETYL)-L-ASPARTATE
    ZIEG, J
    CLAYTON, CE
    ARDESHIR, F
    GIULOTTO, E
    SWYRYD, EA
    STARK, GR
    MOLECULAR AND CELLULAR BIOLOGY, 1983, 3 (11) : 2089 - 2098
  • [4] N-(PHOSPHONACETYL)-L-ASPARTATE (PALA) - CURRENT STATUS
    ROZENCWEIG, M
    ABELE, R
    PICCART, M
    VONHOFF, DD
    MUGGIA, FM
    RECENT RESULTS IN CANCER RESEARCH, 1980, 74 : 72 - 77
  • [5] PHARMACOLOGICAL DISPOSITION OF N-(PHOSPHONACETYL)-L-ASPARTATE IN HUMANS
    LOO, TL
    FRIEDMAN, J
    MOORE, EC
    VALDIVIESO, M
    MARTI, JR
    STEWART, D
    CANCER RESEARCH, 1980, 40 (01) : 86 - 90
  • [6] EFFECT OF URIDINE (URD) ON CLINICAL TOXICITIES DURING N-(PHOSPHONACETYL)-L-ASPARTATE (PALA) TREATMENT
    LEYVA, A
    MCVIE, JG
    LANKELMA, J
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 348 - 348
  • [7] REVERSAL OF TOXICITY AND ANTITUMOR ACTIVITY OF N-(PHOSPHONACETYL)-L-ASPARTATE BY URIDINE OR CARBAMYL-DL-ASPARTATE INVIVO
    JOHNSON, RK
    BIOCHEMICAL PHARMACOLOGY, 1977, 26 (01) : 81 - 84
  • [8] STRUCTURE OF AMPLIFIED DNA IN DIFFERENT SYRIAN-HAMSTER CELL-LINES RESISTANT TO N-(PHOSPHONACETYL)-L-ASPARTATE
    ARDESHIR, F
    GIULOTTO, E
    ZIEG, J
    BRISON, O
    LIAO, WSL
    STARK, GR
    MOLECULAR AND CELLULAR BIOLOGY, 1983, 3 (11) : 2076 - 2088
  • [9] Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer
    Fleming, RA
    Capizzi, RL
    Muss, HB
    Smith, S
    Fernandes, DJ
    Homesley, H
    Loggie, BW
    Case, LD
    Morris, R
    Russell, GB
    Richards, F
    CLINICAL CANCER RESEARCH, 1996, 2 (07) : 1107 - 1114
  • [10] BIOCHEMISTRY AND CLINICAL ACTIVITY OF N-(PHOSPHONACETYL)-L-ASPARTATE - A REVIEW
    GREM, JL
    KING, SA
    ODWYER, PJ
    LEYLANDJONES, B
    CANCER RESEARCH, 1988, 48 (16) : 4441 - 4454